{
    "Trade/Device Name(s)": [
        "Nova Allegro HbA1c Assay",
        "Nova Allegro Analyzer"
    ],
    "Submitter Information": "Nova Biomedical Corporation",
    "510(k) Number": "K221326",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171650"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP",
        "JQT"
    ],
    "Summary Letter Date": "April 25, 2024",
    "Summary Letter Received Date": "April 26, 2024",
    "Submission Date": "November 22, 2024",
    "Regulation Number(s)": [
        "21 CFR 864.7470",
        "21 CFR 862.2400"
    ],
    "Regulation Name(s)": [
        "Glycosylated Hemoglobin Assay",
        "Analyzer"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Total Hemoglobin"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [
        "Capillary (finger-stick)"
    ],
    "Instrument(s)/Platform(s)": [
        "Nova Allegro Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Latex enhanced turbidimetric immunoassay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Test Cartridge",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Nova Allegro HbA1c Assay and Nova Allegro Analyzer for quantitative determination of glycated hemoglobin (HbA1c) in capillary whole blood.",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of glycated hemoglobin (HbA1c) in capillary whole blood obtained from the fingertip for monitoring long-term blood glucose/metabolic control in individuals with diabetes mellitus.",
    "fda_folder": "Hematology"
}